233 related articles for article (PubMed ID: 12972028)
1. The role of EVI1 in normal and leukemic cells.
Buonamici S; Chakraborty S; Senyuk V; Nucifora G
Blood Cells Mol Dis; 2003; 31(2):206-12. PubMed ID: 12972028
[TBL] [Abstract][Full Text] [Related]
2. Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements.
Sitailo S; Sood R; Barton K; Nucifora G
Leukemia; 1999 Nov; 13(11):1639-45. PubMed ID: 10557037
[TBL] [Abstract][Full Text] [Related]
3. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
Fears S; Mathieu C; Zeleznik-Le N; Huang S; Rowley JD; Nucifora G
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1642-7. PubMed ID: 8643684
[TBL] [Abstract][Full Text] [Related]
4. EVI1 Interferes with Myeloid Maturation via Transcriptional Repression of Cebpa, via Binding to Two Far Downstream Regulatory Elements.
Wilson M; Tsakraklides V; Tran M; Xiao YY; Zhang Y; Perkins AS
J Biol Chem; 2016 Jun; 291(26):13591-607. PubMed ID: 27129260
[TBL] [Abstract][Full Text] [Related]
5. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.
Maicas M; Vázquez I; Alis R; Marcotegui N; Urquiza L; Cortés-Lavaud X; Cristóbal I; García-Sánchez MA; Odero MD
Biochim Biophys Acta Gene Regul Mech; 2017 Jun; 1860(6):721-729. PubMed ID: 28391050
[TBL] [Abstract][Full Text] [Related]
6. [EVI1 and its role in myelodysplastic syndrome, myeloid leukemia and other malignant diseases].
Fuchs O
Cas Lek Cesk; 2006; 145(8):619-24. PubMed ID: 16995417
[TBL] [Abstract][Full Text] [Related]
7. Thrombopoietin/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 leukemia.
Nishikawa S; Arai S; Masamoto Y; Kagoya Y; Toya T; Watanabe-Okochi N; Kurokawa M
Blood; 2014 Dec; 124(24):3587-96. PubMed ID: 25298035
[TBL] [Abstract][Full Text] [Related]
8. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.
Yoshimi A; Goyama S; Watanabe-Okochi N; Yoshiki Y; Nannya Y; Nitta E; Arai S; Sato T; Shimabe M; Nakagawa M; Imai Y; Kitamura T; Kurokawa M
Blood; 2011 Mar; 117(13):3617-28. PubMed ID: 21289308
[TBL] [Abstract][Full Text] [Related]
9. Erythroid defects and increased retrovirally-induced tumor formation in Evi1 transgenic mice.
Louz D; van den Broek M; Verbakel S; Vankan Y; van Lom K; Joosten M; Meijer D; Löwenberg B; Delwel R
Leukemia; 2000 Nov; 14(11):1876-84. PubMed ID: 11069022
[TBL] [Abstract][Full Text] [Related]
10. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
[TBL] [Abstract][Full Text] [Related]
11. Leukemogenesis of the EVI1/MEL1 gene family.
Morishita K
Int J Hematol; 2007 May; 85(4):279-86. PubMed ID: 17483069
[TBL] [Abstract][Full Text] [Related]
12. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells.
Senyuk V; Chakraborty S; Mikhail FM; Zhao R; Chi Y; Nucifora G
Oncogene; 2002 May; 21(20):3232-40. PubMed ID: 12082639
[TBL] [Abstract][Full Text] [Related]
13. Fadd and Skp2 are possible downstream targets of RUNX1-EVI1.
Maki K; Sugita F; Nakamura Y; Sasaki K; Mitani K
Int J Hematol; 2013 Jan; 97(1):83-91. PubMed ID: 23250858
[TBL] [Abstract][Full Text] [Related]
14. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML.
Cuenco GM; Nucifora G; Ren R
Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1760-5. PubMed ID: 10677531
[TBL] [Abstract][Full Text] [Related]
15. RUNX1-EVI1 induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice.
Nakamura Y; Ichikawa M; Oda H; Yamazaki I; Sasaki K; Mitani K
Leuk Res; 2018 Nov; 74():14-20. PubMed ID: 30278283
[TBL] [Abstract][Full Text] [Related]
16. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
[TBL] [Abstract][Full Text] [Related]
17. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; van Putten WL; Valk PJ; van der Poel-van de Luytgaarde S; Hack R; Slater R; Smit EM; Beverloo HB; Verhoef G; Verdonck LF; Ossenkoppele GJ; Sonneveld P; de Greef GE; Löwenberg B; Delwel R
Blood; 2003 Feb; 101(3):837-45. PubMed ID: 12393383
[TBL] [Abstract][Full Text] [Related]
18. Molecular analysis of Evi1, a zinc finger oncogene involved in myeloid leukemia.
Lopingco MC; Perkins AS
Curr Top Microbiol Immunol; 1996; 211():211-22. PubMed ID: 8585952
[TBL] [Abstract][Full Text] [Related]
19. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
Katayama S; Suzuki M; Yamaoka A; Keleku-Lukwete N; Katsuoka F; Otsuki A; Kure S; Engel JD; Yamamoto M
Blood; 2017 Aug; 130(7):908-919. PubMed ID: 28630119
[TBL] [Abstract][Full Text] [Related]
20. Activation of a novel gene in 3q21 and identification of intergenic fusion transcripts with ecotropic viral insertion site I in leukemia.
Pekarsky Y; Rynditch A; Wieser R; Fonatsch C; Gardiner K
Cancer Res; 1997 Sep; 57(18):3914-9. PubMed ID: 9307271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
